Sudan ebolavirus

The Native Antigen Company Expands Infectious Disease Portfolio to Include Sudan Ebolavirus Boniface 1976 Glycoprotein

Retrieved on: 
Thursday, December 8, 2022
Medical Devices, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Antigen, Ebolavirus, SEBOV, Infection, HEK 293 cells, Research, Ebola, Disease, Antibody, Cell, Human, Vaccine, Immunoassay, Mortality, Health, EBOV, Sudan ebolavirus

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the worlds leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial release of its Sudan Ebolavirus Boniface 1976 Glycoprotein (SEBOV GP).

Key Points: 
  • The Native Antigen Company (part of LGC Clinical Diagnostics), one of the worlds leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial release of its Sudan Ebolavirus Boniface 1976 Glycoprotein (SEBOV GP).
  • Sudan Ebolavirus is a species of ebolavirus responsible for severe disease in humans, Ebola haemorrhagic fever, for which there are currently no licensed vaccines or treatments available.
  • The Native Antigen Companys SEBOV GP is designed for use in immunoassay and vaccine development to support research into the deadly disease.
  • For further information about The Native Antigen Companys Sudan Ebolavirus Boniface 1976 Glycoprotein, please visit: https://thenativeantigencompany.com/products/ebola-virus-envelope-glycop...

GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting

Retrieved on: 
Thursday, July 22, 2021
Medical specialties, Animal diseases, Infectious diseases, Zoonoses, Biological weapons, Tropical diseases, Sudan ebolavirus, Ebolavirus, Ebola, GeoVax, Zaire ebolavirus, Filoviridae

ATLANTA, GA, July 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines, today announced the presentation of data from a study of its preventive vaccine against Sudan Ebolavirus (SUDV). The presentation titled “A single immunization of guinea pigs with a modified vaccinia Ankara virus producing Sudan virus-like particles protects from Sudan virus lethal challenge,” was delivered by Dr. Delphine Malherbe of the Bukreyev Lab, Department of Pathology, University of Texas Medical Branch, Galveston, Texas, during the Annual Meeting of the American Society for Virology, being held virtually July 19-23.

Key Points: 
  • Challenge of vaccinated animals with guinea pig-adapted SUDV demonstrated a complete protection against death and disease by the prime and the prime-boost regimens.
  • This is the first report that a replication-deficient MVA vector may confer full protection against SUDV after a single dose.
  • David Dodd, GeoVax President and CEO, further commented, The presentation of data from this study further validates our platform and approach to addressing Sudan virus, and we look forward to advancing our vaccine to non-human primate testing.
  • Sudan ebolavirus (SUDV) is one of six known viruses within the genus Ebolavirus (Filoviridae family) and causes Ebola virus disease in humans, with a fatality rate up to 73%.

Soligenix Announces Publication Demonstrating Thermostabilization of Filovirus Vaccine Antigens

Retrieved on: 
Tuesday, September 15, 2020
Medical specialties, Animal diseases, Veterinary medicine, Biological weapons, Tropical diseases, Zoonoses, Animal virology, Ebolavirus, Sudan ebolavirus, Filoviridae, Ebola, Zaire ebolavirus

These most recent results demonstrate the thermostabilization of three virus glycoproteins (from Zaire ebolavirus, Sudan ebolavirus and Marburg marburgvirus), and the identification of key stability-indicating assays to further support mono-, bi- and tri-valent vaccine formulations.

Key Points: 
  • These most recent results demonstrate the thermostabilization of three virus glycoproteins (from Zaire ebolavirus, Sudan ebolavirus and Marburg marburgvirus), and the identification of key stability-indicating assays to further support mono-, bi- and tri-valent vaccine formulations.
  • "The continued advances in the filovirus program demonstrates the program's maturity and overall developability," noted Oreola Donini, PhD, Senior Vice President and Chief Scientific Officer of Soligenix.
  • "The compatibility with thermostabilization, and the identification of key stability indicating assays, are both hallmarks of a potentially broadly applicable vaccine platform.
  • Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines

Retrieved on: 
Thursday, August 13, 2020
Medical specialties, Infectious diseases, Animal diseases, Tropical diseases, Zoonoses, Biological weapons, Sudan ebolavirus, Ebolavirus, Zaire ebolavirus, Filoviridae, Ebola, Marburg virus disease

ATLANTA, GA, Aug. 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today a multi-party collaboration for the development of Sudan ebolavirus (SUDV) and Marburg virus (MARV) vaccine candidates.

Key Points: 
  • ATLANTA, GA, Aug. 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today a multi-party collaboration for the development of Sudan ebolavirus (SUDV) and Marburg virus (MARV) vaccine candidates.
  • David Dodd, GeoVax President and CEO, commented, This exciting collaboration enables us to advance these two critically needed vaccine candidates through nonhuman primate testing.
  • Sudan ebolavirus (SUDV) is one of six known viruses within the genus Ebolavirus (Filoviridae family) and causes Ebola virus disease in humans, with a fatality rate as high as 71%.
  • GeoVaxs current development programs are focused on preventive vaccines against COVID-19, HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines against solid tumor cancers.